Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Background: REDUCE-IT was a double-blind trial that randomized 8,179 statin-treated patients with controlled low-density lipoprotein cholesterol and moderately elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in the primary endpoint, including death from...

Full description

Bibliographic Details
Main Authors: Ballantyne, C.M (Author), Bhatt, D.L (Author), Brinton, E.A (Author), Doyle, R.T., Jr (Author), Gaba, P. (Author), Gibson, C.M (Author), Giugliano, R.P (Author), Granowitz, C. (Author), Jacobson, T.A (Author), Jiao, L. (Author), Juliano, R.A (Author), Ketchum, S.B (Author), Martens, F.M.A.C (Author), Miller, M. (Author), Steg, P.G (Author), Tardif, J.-C (Author), the REDUCE-IT Investigators (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
clinical trials
icosapent ethyl
ischemic events
myocardial infarction
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items